Vir Biotechnology, Inc. VIR Business Segments — Other R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept vir:ResearchAndDevelopmentOther.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s business segments — other r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s business segments — other R&D?
- Vir Biotechnology, Inc. (VIR) reported business segments — other R&D of $18.06M in Q1 2026.
- How has Vir Biotechnology, Inc.'s business segments — other R&D changed year-over-year?
- Vir Biotechnology, Inc.'s business segments — other R&D decreased by 1.8% year-over-year, from $18.39M to $18.06M.
- What is the long-term trend for Vir Biotechnology, Inc.'s business segments — other R&D?
- Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s business segments — other R&D has grown at a -9.8% compound annual growth rate (CAGR), from $96.59M to $70.84M.
- What does business segments — other R&D mean?
- Encompasses miscellaneous research and development expenses not directly attributed to specific clinical trials or personnel, such as laboratory supplies, equipment maintenance, and early-stage discovery research. It provides visibility into the broader operational costs of maintaining an innovation-driven R&D pipeline.